The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review
Open accessAbstract
The diversion, misuse, and non-medically supervised use of buprenorphine and buprenorphine/naloxone by opioid users are reviewed. Buprenorphine and buprenorphine/naloxone are used globally as opioid analgesics and in the treatment of opioid dependency. Diversion of buprenorphine and buprenorphine/naloxone represents a complex medical and social issue, and has been widely documented in various geographical regions throughout the world. We first discuss the clinical properties of buprenorphine and its abuse potential. Second, we discuss its diversion and illicit use on an international level, as well as motivations for those activities. Third, we examine the medical risks and benefits of buprenorphine's non-medically supervised use and misuse. These risks and benefits include the effect of buprenorphine's use on HIV risk and the risk of its concomitant use with other medications and drugs of abuse. Finally, we discuss the implications of diversion, misuse, and non-medically supervised use (including potential measures to address issues of diversion); and potential areas for further research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654
Dole, V. P. (1965) · JAMA · doi:10.1001/jama.1965.03090080008002 · Cited by 1,240
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
Drug addiction: the neurobiology of behaviour gone awry
Volkow, N. D., & Li, T.-K. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1539 · Cited by 625
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577 · cited 1×
“Buprenorphine/naloxone is a first-line option for office-based treatment, with the buprenorphine monoproduct used occasionally for the induction phase [92, 93].”
BackgroundA Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Johnson, R. E. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480200058024 · Cited by 572
Marsch, L. A. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9345157.x · Cited by 553
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
Cited by
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update
(2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000633 · Cited by 412
Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
Davis, M. P., Pasternak, G., & Behm, B. (2018) · Drugs · doi:10.1007/s40265-018-0953-z · Cited by 138
Buprenorphine—Clinically useful but often misunderstood
Butler, S. (2013) · Scandinavian Journal of Pain · doi:10.1016/j.sjpain.2013.05.004 · Cited by 47
Ahmadi, J., & Abtahi, S. (2017) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.59999 · Cited by 6
Metadata
- Authors
- A. Yokell, M., D. Zaller, N., C. Green, T., & D. Rich, J.
- Venue
- Current Drug Abuse Reviewse
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-03-01
- Volume
- 4
- Issue
- 1
- Pages
- 28-41
- ISSN
- 1874-4737 (ISSN-L)
- OpenAlex
- W2031176986
- Cited by
- 398
- References
- 106
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review. https://app.cochat.ai/papers/10.2174/1874473711104010028
- The paper
- A. Yokell, M., D. Zaller, N., C. Green, T., & D. Rich, J. (2011). Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review. Current Drug Abuse Reviewse. https://doi.org/10.2174/1874473711104010028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
